Event Details

Date and Time:

Thursday, May 12th, 2022

Hong Kong/Shanghai/Beijing/Singapore/Kuala Lumpur: 2pm-3pm

Tokyo/Seoul : 3pm-4pm

Omicron moves fast. That makes it difficult to contain - even for China, which tries to promptly stop any outbreak as part of its dynamic zero covid strategy. As Omicron spreads across Asian countries, it is adding uncertainty in markets already concerned about economic recovery, supply chain disruptions, and more. At the same time, public health is pushing forward new avenues for business growth in Asia, as government policies and consumer behaviours around Covid-19 not only reshape the healthcare infrastructure, but redirect entire economic sectors such as tourism and consumer retail trends. Healthcare innovation in Asia has accelerated on all fronts, with vaccinations being disseminated at rapid speed, medical supplies and equipment transforming public health, and closer cooperation between public health and business sectors becoming a new reality. In this virtual programme, we will consider what comes next in the 'pandemic to endemic' transition, learning from the experiences of the rest of the world as well as from public health and industry leaders in Asia.

Please note that this event is limited to senior-level executives and per invitation only. If you are not an existing member of The Economist Intelligence Corporate Network, but would like to learn how you can attend our events, please contact us.


  • Mattie Bekink (China Director of The Economist Intelligence Corporate Network)

    Mattie Bekink

    China Director of The Economist Intelligence Corporate Network

    Mattie Bekink is responsible for the Economist Intelligence Corporate Network’s China strategy, including programme development and client engagement across China.

    Ms Bekink has extensive experience in the public, private and policy sectors. Prior to joining The Economist Group, she was the Executive Director of the Fulbright Commission in the Netherlands. She also ran an eponymous consulting business, advising businesses, universities and non-profit organisations on China policy, strategy, public affairs, and CSR. Ms Bekink practiced law at Skadden, Arps, Slate, Meagher & Flom LLP, has worked with the US-Asia Law Initiative at NYU Law School and the American Bar Association Rule of Law Initiative China Program, and served in the legal department at General Motors China.

    Ms Bekink has a BA in International Relations from Stanford University and a JD from the Georgetown University Law Center.

    view more
  • Amit Raheja (General Manager, Hong Kong at Johnson & Johnson (HK) Ltd)

    Amit Raheja

    General Manager, Hong Kong at Johnson & Johnson (HK) Ltd

    Amit Raheja is the General Manager and a member of the Board of Directors of Johnson & Johnson Hong Kong Ltd. since 2019. Prior to this, he was in Tokyo, Japan for 3 years where he led the turnaround and subsequent divestiture of the Diabetes Care Companies of J&J. Over the past 17 years, he has served in various leadership roles in the Healthcare industry in India, Asia Pacific, Japan and now Hong Kong. He is a proud sponsor of the Community Impact team at Johnson & Johnson Hong Kong.
    Amit also serves as the Chair of the Healthcare Committee at American Chamber of Commerce (AmCham) Hong Kong.
    He has lived and worked in 8 cities across the world and strongly believes in the power of agility. He strongly believes that the healthcare industry can and must play a bigger role in improving the lives of patients around the world through continuous innovation and scientific education.
    He completed his MBA from ISB (Indian School of Business)and has graduated from the ‘Healthcare’ program from Harvard Business School. Prior to joining Johnson & Johnson, Amit was an entrepreneur for 5 years.

    view more
  • Ronald Whelan (Chief Commercial Officer at Discovery Health)

    Ronald Whelan

    Chief Commercial Officer at Discovery Health

    Dr Ronald Whelan is Chief Commercial Officer of Discovery Health, the largest medical insurer in Southern Africa. A medical doctor by training with an MBA, he was Associate Partner at McKinsey where he co-led McKinsey’s healthcare practice across sub-Saharan Africa. He also headed up Healthcare Investments and business development at Spinnaker Growth Partners and was founder of Healthforce, a leading telemedicine player in South Africa. Dr Whelan has over 20 years of experience in clinical and corporate healthcare across 25 countries globally. He is currently leading Discovery’s Covid 19 response and is a Member of South Africa's national private sector steering committee on the Covid19 response and the national vaccination programme.

    view more
  • Jian Chen (CEO of CreditWise Technology)

    Jian Chen

    CEO of CreditWise Technology

    Dr. Jian Chen is the founder and CEO of CreditWise Technologies, Co. Ltd. He also serves as the senior advisor of Caixin Insight Group, a prestigious think tank in China. He previously held the positions of Managing Partner of RQuest Financial Services Group, Managing Director in IFE Group, Risk Modeling Director in Freddie Mac, Director of Credit Risk Management in Fannie Mae. He recently created the COVID-19 Global Risk Index (http://covid19-risk-index.com/) to assess the risk of each country in the pandemic, together with Dr. Zhang, Wenhong of Huashan Hospital.

    Dr. Chen currently holds the academic position of adjunct professor of real estate finance at Fudan university, a senior research fellow at Shanghai Institute of Advanced Finance (SAIF). He also serves as the visiting professor of PKU-Fordham joint PhD program. He previously served as an adjunct professor at Johns Hopkins Carey Business School, where he taught MBA-level finance courses. Dr. Chen’s academic research interests include discrete event modeling, real estate finance and economics, fixed income securities pricing & hedging, consumer behavior modeling, and quantitative risk management.

    Dr. Chen writes column articles for several prominent Chinese newspaper and periodicals, including Wenhui Bao, South Reviews Magazine, CAIXIN Media. Dr. Chen has his BS in EE from Xi’an Jiaotong University, his MS in EE from Shanghai Jiaotong University, and his Ph.D. in Management Science with concentration on Computational Finance, from Robert H. Smith School of Business, University of Maryland at College Park.

    Dr. Chen recently applied the quantitative model of credit risk analysis for the prediction of COVID-19 outbreaks. This approach is proven to be more robust, flexible, and accurate than most traditional epidemiological models. This new approach applies state transition matrix techniques in coronavirus infection and treatment predictions. The key innovation is trifold: 1. It is a flexible model which can predict the intermediate states; 2. It doesn't need too much parameter estimation and is mainly driven by empirical probabilities; 3. It treats all the government preventive measures as embedded in the observed probabilities. Thus, this model greatly improves the predictive power.

    view more